Loading PHARMTIVA
Main navigationPHARMTIVA - Pharma Manufacturing, Innovation & Advancement

Get in touch

+91 9878610760parashar993@gmail.com
Illustrative aseptic manufacturing cleanroom with automated pharmaceutical equipment
Parashar Biswas | Global engineering leadership

Pharmaceutical Engineering, Global Manufacturing & Capital Projects Leadership

With over three decades of global pharmaceutical industry experience, I bring together engineering strategy, manufacturing excellence, capital project leadership, Commissioning, Qualification & Validation (CQV), technology transfer and regulatory compliance to deliver complex transformation and sustainable operational performance.

From concept development to commercial manufacturing.
↓
CAPITAL PROJECTSMANUFACTURING OPERATIONSCQV & TECHNOLOGY TRANSFERGLOBAL DELIVERY
Illustrative pharmaceutical engineer inspecting stainless steel process systems
Engineering leadership.Global delivery.
01 / Executive profile

Transforming Pharmaceutical Engineering Through Strategic Leadership, Innovation & Operational Excellence

My professional journey spans pharmaceutical manufacturing, global engineering delivery, large-scale capital investments, facility design and execution, and regulatory-driven transformation. I have led multidisciplinary initiatives focused on building robust manufacturing capabilities, strengthening operational resilience, accelerating project delivery and ensuring compliance with evolving global regulatory expectations.

Currently serving as a Director at Viatris, Parashar brings extensive leadership experience in delivering complex pharmaceutical engineering, manufacturing and capital investment programs across India, Ireland and international markets. His leadership combines deep technical expertise with strategic business acumen, supported by advanced executive education in management, finance and international business, alongside specialized expertise in pharmaceutical validation technology.

Read the executive profile
Engineering LeadershipDesign, engineering, capital-project execution, CQV and lifecycle delivery.
Global DeliveryMultinational project leadership across Asia, Europe and Africa within matrix organizations.
Strategic LeadershipCapital investment, project governance, stakeholder management, technology transfer and commercialization.
02 / Education & executive development

Engineering Excellence. Strategic Leadership. Global Perspective.

All education & credentials
June 2026

Global Executive Education & Leadership

A graduate of the Global Advanced Management Program (GAMP), delivered by the Indian School of Business (ISB) in collaboration with NUS Business School, Singapore. An ISB alumnus, Parashar brings a global management perspective that integrates strategic leadership, business transformation, financial understanding and international business practices.

2020

Pharmaceutical Validation Technology

Master of Science in Pharmaceutical Validation Technology from Technological University Dublin, Ireland, bringing advanced academic expertise in pharmaceutical validation, quality systems, manufacturing technologies and regulatory compliance. Proud alumnus of TU Dublin.

Executive development

Executive Education & Professional Certifications

Executive education in Financial Management from the Indian Institute of Management Bangalore (IIMB), complemented by the Certified Pharmaceutical Industry Professional (CPIP) credential awarded by ISPE, USA. This combination integrates financial acumen, strategic business understanding and specialised pharmaceutical industry expertise.

03 / Professional journey

Global Programs. Lifecycle Leadership.

Complete career chronology

With a career spanning over three decades since 1991, Parashar Biswas has held progressive engineering, capital projects, manufacturing and strategic leadership roles across leading pharmaceutical organizations, including Viatris, CAI, Ranbaxy, Sandoz and other industry institutions. His experience encompasses global project delivery, engineering excellence, operational transformation and the complete lifecycle management of complex pharmaceutical manufacturing initiatives.

Use premium, illustrative pharmaceutical engineering imagery that reflects global manufacturing infrastructure, advanced engineering, complex capital projects and technology-driven pharmaceutical operations. Images should be representative and conceptual, rather than actual photographs of the named companies or specific projects.

04 / Current major programs | 2023-2027

Delivering advanced manufacturing capabilities through complex program execution

PHARMTIVA brings together facility engineering, engineering design, Commissioning, Qualification & Validation (CQV), advanced manufacturing technologies and technology commercialization to support the successful delivery of complex pharmaceutical manufacturing programs.

India | Approved CAPEX: $110 Mn

Greenfield aseptic manufacturing facility

End-to-end engineering and program delivery for greenfield aseptic manufacturing facilities, integrating facility design, process engineering, utilities, automation, regulatory compliance and CQV to establish future-ready manufacturing operations.

An integrated greenfield manufacturing program encompassing facility planning and design, process and utility engineering, project execution, and comprehensive Commissioning, Qualification and Validation (CQV). The program focuses on establishing a compliant, efficient and future-ready aseptic manufacturing environment.

Explore the program
India / Ireland | CAPEX approved to date: $150 Mn

GLP-1 autoinjector device project: Integrated Medical Device and Combination-Product Manufacturing

Leading project management for medical-device and combination-product manufacturing activities associated with the Wegovy (Semaglutide) program, integrating engineering, manufacturing readiness, technology deployment and regulatory compliance. The project scope encompasses exhibit-batch manufacturing, process and equipment qualification, validation protocols, commercialization readiness and regulatory submission support. It also includes high-speed automated device assembly, labelling and packaging operations, ensuring alignment between manufacturing capability, product quality, operational performance and regulatory expectations.

The program encompasses end-to-end manufacturing readiness for GLP-1 autoinjector devices and combination products, including exhibit-batch manufacturing, process development, qualification and validation, regulatory submission support, and commercialization. It integrates high-speed device assembly, labelling, packaging, and GMP-compliant manufacturing operations to support scalable, reliable, and commercially sustainable production.

Explore combination-product experience
05 / Capital-project leadership

From Strategic Capital Investment to GMP-Compliant Commercial Manufacturing Excellence.

Explore project delivery

Parashar brings comprehensive leadership experience across the pharmaceutical capital project lifecycle, from strategic investment planning, facility conceptualization, and engineering design to procurement, construction, commissioning, qualification, and commercial manufacturing readiness. His integrated approach aligns engineering excellence, regulatory compliance, operational performance, and business objectives to deliver future-ready pharmaceutical manufacturing facilities that are scalable, efficient, and sustainable.

With extensive experience leading complex projects within global matrix organizations, Parashar drives cross-functional collaboration across engineering, manufacturing, quality assurance, regulatory affairs, procurement, technical operations, and strategic external partners. His leadership emphasizes effective project governance, stakeholder alignment, capital expenditure optimization, risk management, and disciplined execution to achieve project milestones, regulatory readiness, and successful transition to commercial operations.

Governance & planning

Strategic Capital Planning & Portfolio Governance

Strategic capital planning and enterprise portfolio management are critical to delivering sustainable business growth and long-term operational excellence in the pharmaceutical industry. This capability encompasses capital investment strategy, portfolio prioritization, PMO leadership, project governance and investment decision-making. It includes evaluating and qualifying projects from concept through execution, aligning capital allocation with business priorities, optimizing resource utilization, managing portfolio interdependencies and establishing robust governance frameworks to ensure investments deliver measurable business value.

Engineering & execution

Greenfield & Brownfield Project Execution

PHARMTIVA provides strategic and technical expertise across the complete lifecycle of pharmaceutical capital projects, covering both greenfield facility development and brownfield expansion, modernization and transformation. Our expertise spans facility planning and design, process and utility engineering, procurement, construction management, project controls, commissioning and qualification. We support projects ranging from conventional finished-dose manufacturing facilities to complex sterile injectables, oncology containment facilities and advanced aseptic manufacturing environments.

CQV & regulatory readiness

A risk-based engineering approach

We integrate engineering risk management, quality-by-design principles and regulatory expectations into every stage of project delivery. Our approach focuses on identifying critical risks early, optimizing engineering decisions, ensuring design integrity and maintaining alignment between project execution, operational requirements and GMP compliance. Drawing on established industry frameworks, including ASTM E2500 and ICH Q9, we incorporate risk assessments, impact assessments, system criticality evaluations, requirements traceability and structured change control into project governance. Our expertise also encompasses validation strategy, commissioning and qualification documentation, and regulatory inspection readiness aligned with US FDA, EU GMP and MHRA expectations.

06 / Selected delivery experience

Specialist technologies. Strategic project leadership. Delivering complex pharmaceutical projects with precision.

$50 Mn complex sterile injectable formulation facility, India | 2015-2017Sterile oncology facility with OEB 4-5 containment and closed-RABS concepts | 2017-2020India-to-Indonesia sterile injectable technology transfer | Completed Q2 2022South Africa brownfield ARV / Prednisone facility | Approx. $29 Mn investmentNigeria greenfield oral solid dosage facility | Approx. $18 Mn investmentSandoz tablet and capsule facility, India | Approx. $29 Mn investment
07 / Global delivery

Global perspectives. Cross-border leadership. Connected execution.

Parashar brings extensive international experience in leading multinational projects and cross-functional teams across Asia, Europe and Africa. His professional exposure spans India, Ireland, Singapore, South Africa, Nigeria and Indonesia, providing a broad understanding of diverse operating environments, business cultures and pharmaceutical manufacturing practices.

His international leadership experience encompasses collaboration with global project teams, engineering consultants, EPCM organizations, contract manufacturing organizations (CMOs), technology and equipment suppliers, and regulatory stakeholders. By aligning diverse capabilities, managing executive relationships and building cross-cultural partnerships, he drives effective decision-making and coordinated delivery across complex pharmaceutical projects and global organizations.

Leadership background
  • India
  • Ireland
  • Singapore
  • South Africa
  • Nigeria
  • Indonesia / Southeast Asia
08 / Research & transformation

Advancing sustainable engineering. Unlocking digital possibilities.

PHARMTIVA explores the intersection of pharmaceutical engineering, digital innovation and sustainable manufacturing. Building on extensive industry experience and executive education, our research focuses on emerging technologies, AI-enabled manufacturing, Digital Twins, Industry 4.0 and sustainable engineering practices that can shape the future of pharmaceutical operations.

Research & insights

ESG Maturity Assessment in Pharmaceutical Manufacturing

Our research introduces a structured approach to evaluating and advancing Environmental, Social and Governance (ESG) maturity in pharmaceutical manufacturing. A research paper published in July 2026, titled “A Proposed ESG Maturity Assessment Model (EMAM) for Pharmaceutical Manufacturing: Framework, Methodology, Validation Approach,” presents a systematic framework for assessing ESG maturity, identifying improvement opportunities and supporting the integration of sustainability into manufacturing strategy and operational excellence. The publication overview is available in our Research & Insights section.

Digital Manufacturing & Artificial Intelligence

Exploring the convergence of advanced manufacturing, digital technologies and artificial intelligence to shape the next generation of pharmaceutical operations. Areas of focus include smart manufacturing, data-driven quality management, AI-enabled process validation, predictive maintenance and intelligent manufacturing systems. The objective is to explore emerging technologies and translate relevant innovations into practical opportunities for operational excellence, compliance and sustainable manufacturing performance.

Professional Affiliations & Industry Engagement

Active engagement with leading professional institutions and knowledge networks reflects a longstanding commitment to continuous learning, industry collaboration and professional development. Professional affiliations include: ISPE – International Society for Pharmaceutical Engineering (since 2006) PDA – Parenteral Drug Association (since 2010) PMI – Project Management Institute (since 2010) ASQ – American Society for Quality (since 2025) ResearchGate – Academic and Research Network (since 2026) These affiliations provide opportunities to exchange industry knowledge, engage with emerging technologies, contribute to professional discussions and remain connected with developments shaping pharmaceutical manufacturing and engineering.

Education & affiliations
09 / Frequently asked questions

Experience. Education. Perspective.

A career shaped by decades of pharmaceutical industry experience, complemented by advanced management education and a global perspective. The programs, insights and professional journey reflect a commitment to continuous learning, industry advancement and translating knowledge into practical solutions. Explore the frequently asked questions to learn more about the experience, qualifications and philosophy behind PHARMTIVA.

Contact Parashar
What is Parashar Biswas's current professional role?

Parashar Biswas as Director, Engineering & Capital Projects at Viatris, with experience supporting pharmaceutical programs across India, Ireland and international markets.

What does his pharmaceutical project experience cover?

His experience spans concept development, design and engineering, procurement, construction, commissioning, qualification, technology transfer, regulatory readiness and commercialization. Manufacturing areas include sterile injectables, oncology, oral solid dosage, biotechnology and combination products.

Which major programs are underway for 2023-2027?

Current programs include an approximately 10,000 square metre greenfield aseptic manufacturing facility in India with $110 million approved CAPEX, and a GLP-1 autoinjector device project involving India and Ireland with $150 million CAPEX approved to date. These are program budgets, not statements of completed expenditure.

Was the India-to-Indonesia technology transfer completed?

Yes. The technology transfer was completed in Q2 2022. The project included facility upgrades, equipment procurement, commissioning and qualification at a third-party CMO facility in Indonesia.

What education and professional certifications has he completed?

Education and professional certification include ISB-NUS GAMP in June 2026, Pharmaceutical Validation Technology at TU Dublin in 2020, an MBA in International Business in 2008, Mechanical Engineering graduation in 1990, IIM Bangalore Financial Management executive education in 2016 and ISPE USA CPIP certification in 2014.

What research has he published?

A July 2026 publication is titled A Proposed ESG Maturity Assessment Model (EMAM) for Pharmaceutical Manufacturing: Framework, Methodology, Validation Approach. Research interests include ESG, sustainable engineering, digital manufacturing, AI, validation science and innovation management.

How can I contact Parashar Biswas?

Parashar is based in Bengaluru, India. Call +91 9878610760 or email parashar993@gmail.com. His LinkedIn profile is linked on the Contact page.

Get in touch

Let’s build something together.

A conversation starts here

Let’s build
something together.

Contact PHARMTIVA founder Parashar Biswas.

Founder contact+91 9878610760Founder emailparashar993@gmail.comLocationBengaluru, India